Cerevance is a drug discovery company advancing treatments for brain diseases. The company’s lead program, Cerevance has 5 compounds under development.. The aim of development for CVN293 is to treat neuroinflammation in ALS and Alzheimer’s disease. Craig Thompson is the current CEO.
×
Cerevance � CVN293
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD